Table 5.
Preclinical and clinical studies where HSP90 inhibitors were combined with other anti-cancer drugs.
| Hsp90 inhibitor | Drugs in combination | Cancer type | Outcome | References |
|---|---|---|---|---|
| Tanespimycin (17-AAG) | Sorafenib (multi-kinase inhibitor) | Melanoma, renal and colorectal cancer | Clinical efficacy in melanoma and renal cancer patients | (164) |
| Tanespimycin | Trastuzumab (anti-HER2 antibody) | HER-2 positive, metastatic breast cancer | Significant anti-cancer activity | (165) |
| Ganetespib (STA-9090) | Vemurafenib (BRAF(V600E) inhibitor) | Melanoma | Inhibition of tumor growth in BRAF-inhibitor sensitive melanoma | (166) |
| Ganetespib | TAK-733 (MEK inhibitor) | Melanoma | Tumor regression in vemurafenib-resistant xenografts | (166) |
| Ganetespib | Capecitabine (DNA synthesis inhibitor) | Colorectal cancer | Improved anti-tumor activity of combinatorial therapy | (167) |
| Ganetespib | STI-A1015 (anti-PD-L1 antibody) | MC38 colon carcinoma and B16 melanoma | Enhanced anti-tumor efficacy of the combinatorial regimen | (168) |
| Luminespib (NVP-AUY922) | Omipalisib (PI3K inhibitor) | KRAS mutant NSCLC | Synergistic anti-tumor effect | (169) |